(Q57982414)

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Alzheimer's disease and Abeta toxicity: from top to bottom

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin-1beta?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Synaptic plasticity: one STEP at a time

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Regulation of NMDA receptor trafficking by amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Tau is essential to beta -amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Possible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium Homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Diversity of amyloid beta protein fragment [1-40]-formed channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Interaction of beta-amyloid peptides with integrins in a human nerve cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The amyloid beta peptide (Abeta(1-40)) is thermodynamically soluble at physiological concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The metallobiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Hydrogen peroxide mediates amyloid beta protein toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid-beta binds catalase with high affinity and inhibits hydrogen peroxide breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Methionine regulates copper/hydrogen peroxide oxidation products of Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Rapid characterization of amyloid-beta side-chain oxidation by tandem mass spectrometry and the scoring algorithm for spectral analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Dityrosine as a product of oxidative stress and fluorescent probe.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Gossypin protects primary cultured rat cortical cells from oxidative stress- and beta-amyloid-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Bilobalide and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Therapeutic treatments for Alzheimer's disease based on metal bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397

The Aβ Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction†

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796708.2.4.397